This AI trading robot from Day Trader ($2K per position): Medium Volatility Stocks for Active Trading (TA&FA), was a top performer in our robot factory over a month, generating 7.11% for OCGN.
OCGN, a medium volatility stock, has been actively traded using both technical analysis (TA) and fundamental analysis (FA) through an AI trading robot from Day Trader that costs $2K per position. This trading robot has been a top performer in the robot factory over a month, generating a 7.11% return for OCGN. However, the recent MACD histogram turning negative on April 25, 2023, is a bearish signal indicating a potential decline in the stock's price going forward.
Tickeron's A.I.dvisor has conducted a historical analysis on 49 instances where the MACD histogram turned negative, revealing that in 47 of the 49 cases, the stock moved lower in the following days. This puts the odds of a downward move at 90%. Therefore, traders and investors should be cautious when trading OCGN, especially given the current bearish signal.
Fundamentally, OCGN's last earnings report on February 28 showed earnings per share of -10 cents, meeting the estimate of -10 cents. This indicates that the company is meeting expectations but not generating a profit yet. With 732.65K shares outstanding, the current market capitalization sits at 163.03M, reflecting the stock's perceived value by the market.
The technical analysis of OCGN's MACD histogram indicates a potential decline in the stock's price going forward, and the fundamental analysis shows that the company is not yet generating a profit. These factors should be taken into consideration by traders and investors when making trading decisions on OCGN.
The Moving Average Convergence Divergence (MACD) for OCGN turned positive on March 19, 2024. Looking at past instances where OCGN's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on March 13, 2024. You may want to consider a long position or call options on OCGN as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where OCGN advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 110 cases where OCGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for OCGN moved out of overbought territory on March 28, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 43 cases where OCGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OCGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
OCGN broke above its upper Bollinger Band on March 20, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OCGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.246) is normal, around the industry mean (26.928). P/E Ratio (0.000) is within average values for comparable stocks, (127.075). OCGN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.205). Dividend Yield (0.000) settles around the average of (0.029) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (432.598).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the development and commercialization of therapies for eye diseases
Industry Biotechnology